- MediPharm Labs wholly owned subsidiary Harvest Medicine has
published a study in the peer-reviewed American Journal of
Endocannabinoid Medicine.
- This is the largest peer reviewed published study of its kind
on Fibromyalgia and cannabis, with over 800 patient
assessments.
- Between baseline and follow-up appointments, 75% of patients
saw a significant decrease in their self-reported illness severity
and the study reported reductions in depression and anxiety
scores.
- The study data shows that medical cannabis may play an
effective role in the management of fibromyalgia and
associated symptoms of depression and anxiety.
TORONTO, Aug. 31,
2023 /PRNewswire/ - MediPharm Labs Corp. (TSX:
LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or
the "Company") a pharmaceutical company specialized in
precision-based cannabinoids, is pleased to announce that Harvest
Medicine's study entitled, "Self-Reported Effects of Illness
Severity, Depression and Anxiety in Fibromyalgia Patients: A Large
Retrospective Case Series" has been published in the
peer-reviewed American Journal of Endocannabinoid Medicine. Harvest
Medicine Inc. ("Harvest Medicine" or "HMED") includes a medical
clinic network, and is a wholly owned subsidiary of MediPharm
Labs.
The retrospective study was led by HMED and reviewed data from
805 patients who indicated fibromyalgia as a primary reason for
seeking medical cannabis and had a minimum of one follow-up
assessment. The majority of patients (76.1%) reported using CBD
oil, which aligns with the current practice guidelines for
authorizing medical cannabis as an adjuvant therapy for managing
chronic pain.
The primary findings from the present study include a
significant reduction in all three scores measuring depression,
anxiety, and illness severity between baseline and first
follow-up.
- 75% of patients saw a decrease in their self-reported illness
severity, which may include chronic pain, insomnia, and
fatigue.
- Anxiety scores were improved in 22% of those patients reporting
mild-moderate severity, and in 48% of patients reporting severe
anxiety.
- 27% of patients reporting mild-medium depression noted a
reduction in symptoms, while 48% of patients reporting severe
depression showed a reduction in PHQ-9 score.
The validated study data shows that medical cannabis may play an
effective role in the management of fibromyalgia and
associated symptoms of depression and anxiety, and that additional,
similar studies are recommended.
"Since 2017, Harvest Medicine's primary objective is to improve
the quality of patients' lives by providing access to medical
cannabis and offering the highest standard of medical care with a
scientifically informed approach" commented Barbara Vermeulen, Director of Harvest Medicine.
"We will continue to advocate for patients to maintain access to
physician guided consultations and education, with the goal of
reducing stigma among health care professionals and advancing
patient outcomes".
Details on the study can be viewed on American Journal of
Endocannabinoids Website.
MediPharm remains focused on investing in clinical research and
supporting the development of future cannabis derived
pharmaceutical drugs. Consistent with this commitment, the Company
continues to supply sponsors and investigators with
cannabis-derived study drugs, placebos, and other services and
assistance as may be required during the course of the
studies.
Summary of MediPharm Labs Clinical Projects
Researcher
|
Indication
|
Phase
|
Recent
Milestone
|
McMaster
University
|
Treatment of
post-surgical pain
|
Two
|
CTM delivered and
enrollment in Q1 2023.
Patient dosing
commenced in Q2 2023.
|
University Health
Network - Toronto
|
Improving Pain
Disability with
the Use of Oral Cannabinoids
|
Pilot
|
CTM Delivered
and
enrollment clinic in Q1
2023.
|
McMaster
University
|
Insomnia in
depressive
disorder
|
Two
|
CTM
Shipment in Q1 2023.
Patient dosing
commenced in Q2 2023.
|
Centre for Medical
Cannabis Research
|
PK of single dose
THC/CBD in
healthy adult controls and
kidney disease
|
One
|
First patient dosed
January 2023.
|
University of
Manitoba
|
Chronic Headaches
in
Adolescents
|
Two
|
Health Canada
approval
Dec 2022. CTM
shipment in Q1 2023.
|
Harvest Medicine
Clinic (MediPharm
Owned)
|
Self-Reported Effects
of Illness
Severity, Depression and
Anxiety in Fibromyalgia Patient
|
Real
World
Evidence
|
Peer reviewed and
published in American
Journal of
Endocannabinoid
Medicine in 2023.
|
Harvest
Medicine
Clinic (MediPharm
Owned)
|
Medical cannabis use
impact
on anxiety and depression
|
Real
World
Evidence
|
Peer reviewed and
published in American
Journal of
Endocannabinoid
Medicine in 2022.
|
In addition to institutionally led studies, the Company is also
providing API and clinical trial material to various pharmaceutical
companies for commercial projects involving cannabis-derived drugs.
The timelines for both institutional and industry research are long
by nature with positive outcomes uncertain.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development
and manufacture of purified, pharmaceutical-quality cannabis
concentrates, active pharmaceutical ingredients (API) and advanced
derivative products utilizing a Good Manufacturing Practices
certified facility with ISO standard-built clean rooms. MediPharm
Labs has invested in an expert, research driven team,
state-of-the-art technology, downstream purification methodologies
and purpose-built facilities for delivery of pure, trusted and
precision-dosed cannabis products for its customers. MediPharm Labs
develops, formulates, processes, packages, and distributes cannabis
and advanced cannabinoid-based products to domestic and
international medical markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug
Establishment License from Health Canada, becoming the only company
in North America to hold a
commercial scale domestic Good Manufacturing License for the
extraction of multiple natural cannabinoids. The Company carries
out its operations in compliance with all applicable laws in the
countries in which it operates.
In 2023, MediPharm acquired VIVO Cannabis Inc. which expanded
MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce
platform, and in Australia and
Germany through Beacon Medical PTY
and Beacon Medical GMBH. This acquisition also included Harvest
Medical Clinics in Canada which
provides medical cannabis patients with physician consultations for
medical cannabis education and prescriptions.
Cautionary Note Regarding
Forward-Looking Information:
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
statements") within the meaning of the applicable Canadian
securities legislation. All statements, other than statements of
historical fact, are forward-looking statements and are based on
expectations, estimates and projections as at the date of this news
release. Any statement that involves discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
assumptions, future events or performance (often but not always
using phrases such as "expects", or "does not expect", "is
expected", "anticipates" or "does not anticipate", "plans",
"budget", "scheduled", "forecasts", "estimates", "believes" or
"intends" or variations of such words and phrases or stating that
certain actions, events or results "may" or "could", "would",
"might" or "will" be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking
statements. In this news release, forward-looking statements relate
to, among other things, opportunities for future clinical research
projects and the future supply to the global pharmaceutical
industry, future marketable pharmaceutical products, and future
Canadian and international commercial products that leverage MPL's
unique Pharma expertise. Forward-looking statements are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable, are subject to known and unknown risks,
uncertainties, and other factors which may cause the actual results
and future events to differ materially from those expressed or
implied by such forward-looking statements. Such factors include,
but are not limited to: general business, economic, competitive,
political, and social uncertainties; the inability of MediPharm
Labs to obtain adequate financing; the delay or failure to receive
regulatory approvals; and other factors discussed in MediPharm
Labs' filings, available on the SEDAR website at www.sedar.com.
There can be no assurance that such statements will prove to be
accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on the forward-looking
statements and information contained in this news release. Except
as required by law, MediPharm Labs assumes no obligation to update
the forward-looking statements of beliefs, opinions, projections,
or other factors, should they change.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medipharm-labs-publishes-study-investigating-medical-cannabis-impacts-on-anxiety-and-depression-outcomes-in-fibromyalgia-patients-301914834.html
SOURCE MediPharm Labs Corp.